Introduction
Despite prompt application of reperfusion therapies a large number of patients with extensive myocardial infarction continue to experience adverse left ventricular (LV) remodelling and heart failure, and no treatment has proven to effectively prevent this adverse outcome. 1, 2 Calpains are a family of Ca 2þ -dependent cysteine proteases that participate in a wide variety of cellular functions. Among them, calpain-1 and calpain-2 are ubiquitously expressed and regulated by the intracellular Ca 2þ concentration and by their endogenous inhibitor calpastatin.
Under pathologic conditions in which Ca 2þ homeostasis is lost, as occurs during ischemia/reperfusion, inappropriate calpain activation takes place and contributes to myocardial injury through the proteolysis of a wide variety of proteins. 3, 4 The activation of calpains does not occur during ischemia but upon reperfusion, when intracellular pH (pHi) normalizes, and calpain inhibition at the time of reperfusion has been proposed as a potential therapeutic strategy to limit infarct size in preclinical studies. 5 It has been suggested that calpains also participate in the progression of adverse post-infarction remodelling, but evidence is not consistent. Disruption of calpain-1 and calpain-2 by using a cardiomyocyte-specific knockout of the calpain small subunit 1, Capn4, reduced ventricle dilatation, dysfunction and mortality at 30 days of infarction. 6 Similar results have been obtained in transgenic mice ubiquitously overexpressing the endogenous calpain inhibitor calpastatin. 7 Conversely, increased calpain activity induced by deleting calpastatin has been described to exacerbate post-infarct ventricular remodelling, contractile dysfunction and mortality rate. 8 In contrast, in a recent study overexpression of calpastatin resulted in impaired scar healing and higher incidence of cardiac rupture and mortality. 9 Furthermore, cardiac-specific knockout of Capn4 increased heart remodelling and ventricular dysfunction in mice subjected to hemodynamic stress with isoproterenol. 10 In addition to these contradictory results, the fact that calpastatin overexpression has been associated with the development of dilated cardiomyopathy indicates that the results obtained in transgenic mice with constitutive alterations of the calpain/calpastatin system have to be interpreted with caution. 11 Moreover, all these studies use experimental models of permanent occlusion of the left anterior descending artery, which do not reflect the current clinical practice in which the rapid restoration of coronary blood flow is the cornerstone of myocardial infarction treatment. As far as we know, there are no studies analysing whether pharmacological inhibition of calpains attenuates the development of ventricular remodelling and dysfunction observed after a transient coronary occlusion.
The calpain inhibitor {(1S)-1[(((1S
-1-benzyl-3-cyclopropyl-amino-2,3-dioxopropyl)amino)carbonyl]-3-methylbutyl} carbamic acid 5-mehoxy-3-oxapentyl ester, SNJ-1945, was specifically designed by Senju Pharmaceutical Co., Ltd. to increase its water solubility and bioavailability, 12 and its pharmacokinetic properties were evaluated in the retina after oral administration. 13 Given orally, SNJ-1945 ameliorated retinal diseases, [14] [15] [16] [17] and induced neuroprotection in models of experimental autoimmune encephalomyelitis, 18, 19 and cerebral ischemia in mice. 20 More recently, its intraperitoneal administration before a brief coronary occlusion, ameliorated post-ischemic LV dysfunction (stunning). 21 In the present study, we examine whether pharmacological calpain inhibition by delayed oral administration of SNJ-1945, 24 h after prolonged coronary occlusion, ameliorates adverse remodelling after infarction independently of its cardioprotective effect during the acute phase of reperfusion by modulating the inflammatory, hypertrophic and fibrotic response to a transient coronary occlusion.
Methods
The experimental procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the United States National Institute of Health (NIH Publication Eighth Edition, 2011), and were approved by the Research Commission on Ethics of the Hospital Vall d'Hebron.
In vivo myocardial infarction
Male Sprague-Dawley rats (250-300 g) were premedicated with atropine (0.05 mg/kg i.p.), anaesthetized with ketamine (75 mg/kg i.p.) and xylazine (10 mg/kg i.p.), and mechanically ventilated (Inspira ASV, Harvard Apparatus). Anaesthesia was maintained with 1% isoflurane. Rats were subjected to 30 min left anterior descending coronary artery (LAD) ligation followed by reperfusion as described previously.
5 Buprenorphine (0.05mg/kg per 12 h, subcutaneously) was given for the first 48 h of reperfusion. Rats with lack of ST-elevation during ischemia or lack of ST-recovery at reperfusion were excluded from further evaluation. The animals were sacrificed by lethal intraperitoneal dose of sodium pentobarbital (100 mg/kg) and previous subcutaneous injection of buprenorphine (0.1mg/kg).
SNJ-1945 administration
SNJ-1945 was suspended in saline containing 0.5% carboxymethyl cellulose. The initial oral doses of SNJ-1945 tested in the in vivo studies were selected based on dose-effect studies performed in isolated hearts perfused in a Langendorff system and subjected to 40 min of ischemia and reperfusion, as described in Supplementary material online, Figure S1 , and the pharmacokinetic parameters for SNJ-1945 obtained by Shirasaki et al. 13 The final oral dose of SNJ-1945 used in the study was determined by measuring calpain activity in rats receiving the drug (30, 60, and 120 mg/kg) or 0.5% carboxymethylcellulose by oral gavage before LAD occlusion as shown in Supplementary material online, Figure S2 . The same effective dose was used in those animals receiving intraperitoneal drug administration.
Experimental protocols
The effect of the calpain inhibitor SNJ-1945 on the extent of infarct size was analysed in rats receiving a single intraperitoneal injection of SNJ-1945 (120 mg/kg, n = 8) or its vehicle (0.5% carboximethyl cellulose, n = 8) 5 min before starting reperfusion. After 24 h of reperfusion, hearts were excised, mounted in a Langendorff apparatus, and perfused with saline for blood removal. The LAD was reoccluded and hearts were perfused with 5% Evans blue to delineate the area at risk. Hearts were cut into five transverse sections that were incubated at 37 C in 1% triphenyltetrazolium chloride (Sigma-Aldrich) for 15 min, and imaged. The area at risk and the area of necrosis were measured semi-automatically (Image Pro-Plus software, Media Cybernetics) in the digitalized images. Infarct size was calculated as a percentage of necrosis at the region at risk. 22 The effect of SNJ-1945 on post-infarct remodelling and heart function was analysed in 48 rats reperfused for 21 days (n = 12 per group). The different experimental groups are shown in Figure 1A . In the acute group, SNJ-1945 (120 mg/kg þ 0.5% carboximethyl cellulose) was administered intraperitoneally 5 min before starting reperfusion. In the chronic group, SNJ-1945 (120 mg/kg þ0.5% carboximethyl cellulose) was administered orally over 14 days starting after 24 h of reperfusion. The delayed administration of the drug allow us to determine whether calpain inhibition alters myocardial remodelling by a direct modulation of the mechanisms responsible of the process and not just by reducing the cell death occurring during the acute phase of reperfusion. In the last group, acute and chronic administration of SNJ-1945 were combined (Ac þ Chr).
Echocardiographic analysis
Rats underwent transthoracic echocardiography at baseline (before surgery), and at 7 and 21 days after surgery. Echocardiography was performed using a Vivid Q portable ultrasound system with a i12L-RS 13MHz transducer (GE Healthcare) as described earlier. 23 The left ven- 
Histology and immunohistochemistry
After 21 days of reperfusion hearts were fixed in buffered 4% paraformaldehyde and embedded in paraffin for histological evaluation. The scar area, expressed as the percentage of the fibrotic area to left ventricular area, was determined in sections at the papillary muscles level stained with Picrosirius red (Sigma-Aldrich) as previously described. 23 Interstitial collagen deposition was assessed in the post-eroseptal non-infarcted myocardium where six random photomicrographs from each heart (n = 6 per group) were taken at Â200 magnification.
Mean cardiomyocyte cross-sectional area was measured in sections stained with hematoxylin and eosin. At least 50 random cells from each heart (n = 6 per group) were measured at Â400 magnification. Infiltration of inflammatory cells in the infarcted and non-infarcted myocardium was analysed by immunohistochemistry in hearts reperfused for 3 days. Sections were probed with CD68 (AbD Serotec) for monocytes/macrophages and CD3 (Dako) for T-cells, incubated with a biotinylated-secondary antibody (1:200, ABC Peroxidase standard staining kit, Thermo Scientific) and visualized using 3,3'-diaminobenzidine (DAB, Sigma). Six random photomicrographs from the infarct area and six from the non-infarcted area for each heart (n = 6 per group) were taken at Â200 magnification. An investigator blinded to the treatment protocols performed the analyses using NIH Image J 1.63 software.
Western-blot, zymography, and RT-PCR
Myocardial samples from non-ischemic areas were homogenized as previously described. 5 For determination of NF-OEB translocation to the nucleus, an enriched nuclear fraction was prepared using Nuclear Extract Kit (Active Motif, USA) following the manufacturer's protocol.
Proteins were separated by Western blot as previously described.
5
Primary antibodies used were raised against calpain-
, histone H3 (Abcam), and vimentin (Santa Cruz). Protein bands were detected by chemiluminiscence (SuperSignal West Dura Extended Duration Substrate, Pierce) and quantified using a charge-coupled device system (Image Reader LAS-3000, Fujifilm) and image analysis software (Image Gauge, Fujifilm). Activity of MMP-2 was evaluated by gelatin zymography as described. 24 Briefly, myocardial preparations obtained from rats reperfused for 21 days (control group) were run on a 10% polyacrylamide gel copolymerized with 1.5 mg/mL gelatin. After washing with 2.5% Triton X-100, gels were cut into strips and incubated separately, overnight, in zymography buffer with SNJ-1945 at the concentrations of 5, 10, and 50 mM, DMSO as a vehicle control or the selective MMP inhibitor ONO-4817 (50 mM, Tocris). We further examined MMP-2 activity in samples prepared from animals receiving SNJ-1945 by oral gavage and reperfused for 21 days (Chronic group). Gels were stained in 0.25% Coomassie Brilliant blue G, 40% methanol, and gelatinolytic activities quantitated after destaining. Total RNA was extracted from ischemic and non-ischemic area of heart samples using TRIsureTM reagent (BIOLINE, UK) following the manufacturer's protocol. Quantitative RT-PCR was performed using Taqman universal PCR master mix (Applied Biosystems, USA). The amplification program consisted of 50 C for 2 min, 95 C for 10 min and 40 cycles of 95 C for 15 s and 60 C for 1 min and was performed in a 7900HT Fast
Real-Time PCR System (Applied Biosystems, USA). Primers used for ANP, BNP, calpain-1, collagen I, IL-1b, Myh6, Myh7, TNF-a, TGF-b1, and GADPH were purchased from Thermofisher (Rn00561661_m1, Rn04219558_g1, Rn00569689_m1, Rn01463848_m1, Rn00580432_m1, Rn00691721_g1, Rn01488777_g1, Rn99999017_m1, Rn00572010_m1, and Rn01775763_g1, respectively).
Experiments in cultured cardiac fibroblasts
The animals were sacrificed by lethal intraperitoneal dose of sodium pentobarbital (100 mg/kg) and previous subcutaneous injection of buprenorphine (0.1 mg/kg). Hearts were excised and left ventricles were minced and digested in an enzymatic solution (DMEM (Sigma) þ penicillin/streptomycin 1Â þ 0.1% tripsin þ 100 u/mL collagenase I). Fibroblasts were collected by centrifugation, resuspended in Dulbecco's modified Eagle's medium containing 10% FBS, and seeded onto tissue culture dishes. All fibroblasts were used from the first two to four generations. Transforming grow factor b1 (TGF-b1) was used to promote the activation of fibroblasts. Fibroblast were incubated with TGF-b1 (5 ng/mL, Abcam) and with or without 10 mM SNJ-1945. Calpain activity was determined by using the fluorogenic substrate t-BOC-Leu-Met-CMAC (Sigma-Aldrich) added to final concentration of 10 mM as previously described. 25 Collagen production was evaluated using Sirius Red
Collagen Detection Kit (Chondrex) following the manufacturer's protocol after 24 h of TGF-b1 stimulation, and a-SMA was measured by western blot as described in the previous section.
Statistical analysis
Data analysis was performed using SPSS for Windows. Means between groups were compared by one-way ANOVA or unpaired t-test. Least significant square test was applied as post hoc test when significant differences were observed. Repeated measures ANOVA and Dunnett's post hoc test were used to compare temporal differences. Assumption of normality was examined in SPSS before the statistical analysis using the Shapiro-Wilk test. P < 0.05 was considered to be statistically significant. All results are expressed as mean ± S.E.M.
Results

Dose-dependency and inhibitory specificity
Studies performed in isolated rat hearts subjected to ischemia/reperfusion showed that perfusion with SNJ-1945 produces a dose-dependent reduction in calpain-specific a-fodrin breakdown products, reflecting calpain inhibition (see Supplementary material online, Figure S1 ). According to these data and the pharmacokinetic parameters of SNJ-1945, 13 rats received orally (by gavage) the drug at the doses of 30, 60 or 120 mg/kg. In our experimental conditions, proteolisis of a-fodrin measured after 60 min of reperfusion was significantly reduced in rats treated with 120 mg/kg SNJ-1945 (see Supplementary material online, Figure S2 ). This concentration is similar to that used in previous studies. 14, 26 To discard the possibility that the effects of SNJ-1945 were consequence of its inhibitory action on MMP-2, 24 the gelatinolytic activity of MMP-2 was measured by zymography in samples incubated with different concentrations of SNJ-1945. The results obtained (see Supplementary material online, Figure S3 ) demonstrated that SNJ-1945 does not inhibit the MMP-2 activity at the concentrations tested, supporting that calpain inhibition is its primary mechanism of action.
Administration of SNJ-1945 immediately before reperfusion reduces infarct size
Intraperitoneal administration of SNJ-1945 did not modify systemic blood pressure or heart rate during the 24 h of reperfusion. There were no significant differences between groups in the mass of myocardium at risk (31.8 ± 2.9% in control group vs. 30.3 ± 2.4% in SNJ-1945 group, P = ns) while infarct size was reduced by 25% (49.4 ± 1.8% in control group vs. 36.9 ± 3.2 in SNJ-1945 group, P = 0.005, see Supplementary material online, Figure S4A ). fragments of a-fodrin (45% decrease, P = 0.001; see Supplementary material online, Figure S4B ).
Delayed, oral administration of SNJ-1945 attenuates calpain activation
Calpain-1 and calpain-2 protein content in the non-infarcted myocardium increased during reperfusion and was not modified by neither acute nor chronic treatment with SNJ-1945 ( Figure 1B) . Calpain-1 mRNA content was elevated in the control group respect to sham operated group (55% increase, P = 0.006) with no significant effect of SNJ-1945 treatment. The content of calpastatin, endogenous calpain inhibitor that is also a well-known calpain substrate, was reduced in reperfused control hearts. This reduction was attenuated by both, acute and chronic SNJ-1945 administration when compared to sham operated animals, but more markedly by chronic than by acute treatment (P = 0.006 and P = 0.035, respectively). In agreement with these results, bands corresponding to 145/150 kDa a-fodrin fragments were reduced with either the acute or chronic treatment. Although combination of acute and chronic administration of SNJ-1945 showed a trend towards a higher inhibition of calpain, the improvement was statistically non-significant with respect the individual treatments ( Figure 1B ).
Oral, long-term administration of SNJ-1945 attenuates adverse post-infarction remodelling
From the 48 rats subjected to ischemia and 21 days of reperfusion protocol 38 were included in the study. Mortality rate was 12.5% with no differences in survival rate between groups (4 rats during surgery and 2 rats at 12 and 24 h of reperfusion). Four animals were excluded due to lack of confirmatory ST-segment shift during ischemia. Baseline echocardiographic evaluation did not show any difference between groups. Myocardial infarction resulted in a progressive increase in LVEDD and LVESD and a decrease in FS (Figure 2A) . No significant changes in LVPW and IVS were reported. LV dilation and dysfunction were significantly attenuated in the groups receiving SNJ-1945 during the acute phase of reperfusion as compared to control rats (Acute and Ac þ Chr groups) when measured at 1 week of reperfusion and also at 21 days of reperfusion in the chronic group. No significant differences in echocardiographic parameters were observed between the acute and chronic treatment at the end of the experiment. The scar size after 21 days of reperfusion was 31.8 ± 2.1% in the control group. Both, intraperitoneal administration of SNJ-1945 at the time of reperfusion and oral administration starting after 24 h of reperfusion attenuated the scar area (29.1% in the acute group, P = 0.002 and 22.7% in the chronic group, P = 0.036; Figure 2B ).
The combination of acute and chronic administration of SNJ-1945 did not result in a statistically significant improvement with respect the individual treatments, although a trend towards a more effective attenuation of LV dilatation, increased FS and reduced scar area were observed.
Long-term, but not acute administration of SNJ-1945 limits cardiomyocyte hypertrophy and interstitial collagen deposition in non-infarcted myocardium
The cardiomyocyte cross-sectional area in the non-ischemic myocardium, indicative of hypertrophy, was increased in the control group respect to sham operated group. Chronic but not acute inhibition of calpains with SNJ-1945 significantly reduced cardiomyocyte hypertrophy (P = 0.041 in the chronic group and P = 0.021 in the Ac þ Chr group, Figure 3A) . Furthermore, b-MHC protein levels, b-MHC/a-MHC ratio and ANP and BNP mRNA levels were increased in control group, providing further evidence of a hypertrophic phenotype, and attenuated only in groups treated chronically with SNJ-1945 (P = 0.034 in the chronic group and P = 0.015 in the Ac þ Chr group for b-MHC/a-MHC ratio, Figure 3B ; P = 0.020 in the chronic group and P = 0.007 in the Ac þ Chr group for ANP, Figure 3C ; and P = 0.022 in the chronic group and P = 0.020 in the Ac þ Chr group for BNP, Figure 3D ). No significant additive effect was observed when both treatments were combined. Myocardial infarction increased interstitial collagen deposition in the non-infarcted area in all groups. Chronic oral administration with SNJ-1945, but not acute treatment, reduced the amount of interstitial collagen (P = 0.029 in the chronic group and P = 0.109 in the acute group).
No further reduction in interstitial fibrosis was observed when SNJ-1945 was given during the acute and chronic phase of reperfusion (P = 0.016, Figure 4A ). In line with these results, expression of collagen ( Figure 4B ) and the protein content of a-SMA ( Figure 4C) were reduced in the noninfarcted area of hearts receiving chronic treatment (P = 0.026 in the chronic group and P = 0.008 in the Ac þ Chr group for collagen and P = 0.008 in the chronic group and P = 0.002 in the Ac þ Chr group for a-SMA respect to Control group). Intracellular TGF-b1 expression and phosphorylation of Smad2/3 markedly increased in control group ( Figure  4D-E) . SNJ-1945 administration produced a trend towards attenuated TGF-b1 expression and reduced phosphorylation of Smad2/3 in the acute group (P = 0.065 and P = 0.070, respectively, vs. control group) that reached statistical significance in the groups receiving chronic oral administration (P = 0.032 in the chronic group and P = 0.024 in the Ac þ Chr group respect to control group for TGF-b1 expression, Stimulation of cultured cardiac fibroblasts with TGF-b1 increased calpain activity and the synthesis of collagen and a-SMA ( Figure 5) . These results are in agreement with previous data obtained in primary human lung fibroblasts suggesting a crosstalk between calpain activation and TGF-b1. 27 The addition of SNJ-1945 before incubation of the cells with TGF-b1 prevented calpain activation (P < 0.001) and this effect correlated with reduced production of collagen (P = 0.015) and a-SMA (P = 0.027).
Calpain inhibition attenuates inflammatory cell infiltration in ischemic and remote myocardium
Inflammatory cell infiltration was determined in a subgroup of hearts reperfused for 3 days (n = 4 per group). Previous results, 28 indicate that at this day of reperfusion infiltration of macrophages corresponding to the proinflammatory M1 population is maximal, and becomes negligible after 21 days. The results demonstrate that both, acute and chronic calpain inhibition attenuate infiltration of monocytes/macrophages (P < 0.001 in the acute group and P = 0.031 in the chronic group) and T-cells (P = 0.016 in the acute group and P = 0.022 in the chronic group) in the ischemic area (see Supplementary material online, Figure S6 ) and in the non-ischemic area (P = 0.009 in the acute group and P = 0.017 in the chronic group for CD68þ cells and P = 0.011 in the acute group and P = 0.016 in the chronic group for CD3þ cells, Figure 6 ) with no significant additive effect when acute and chronic treatments were combined. Consistently, the expression levels of the proinflammatory markers IL1b and TNF-a, were significantly reduced in the ischemic (see Supplementary material online, Figure S5 ) and non-ischemic area ( Figure  6 ) by acute (P = 0.018 and P = 0.023 in the ischemic area and P < 0.001 and P = 0.028 in the non-ischemic area) and chronic calpain inhibition (P = 0.013 and P = 0.041 in the ischemic area and P = 0.026 and P = 0.019 in the non-ischemic area).
Oral administration of SNJ-1945 attenuates NFOEB activation
Calpains have been associated to the degradation of the NF-OEB inhibitor IOEB, a necessary step for translocation of NF-OEB to the nucleus and activation. 29 A significant reduction in the levels of IOEB were observed in the cytosolic fraction from the non-ischemic myocardium of control hearts compared to the sham operated group ( Figure 7A ) and these results correlated with increased protein levels of p65 subunit of NF-OEB in the nuclear fraction ( Figure 7B ). Chronic but not acute administration of SNJ-1945 significantly attenuated the degradation of IOEB (P = 0.006 in the chronic group and P = 0.002 in the Ac þ Chr group) and reduced the translocation of NF-OEB to the nucleus (P = 0.017 in the chronic group and P = 0.012 in the Ac þ Chr group).
Discussion
The present study identifies pharmacological inhibition of calpains as a promising, feasible and effective strategy to limit post-infarction myocardial remodelling and dysfunction. Our results demonstrate that delayed, long-term oral administration of a calpain inhibitor attenuates ventricular remodelling and dysfunction by modulating the hypertrophy of cardiomyocytes, the deposition of collagen and the infiltration of inflammatory cells in the non-infarcted myocardium. Our study also suggests that these effects are mediated by an attenuation of NF-OEB activation. Previous studies in transgenic models with altered calpain/calpastatin system subjected to permanent coronary occlusion provided inconsistent results on adverse myocardial remodelling. Reduction of calpain activity by cardiomyocyte-specific deletion of both, calpain-1 and calpain-2, 6 or overexpression of calpastatin, 7 remodelling and dysfunction, while calpain activation by calpastatin deletion had the opposite effect. 8 On the contrary, a recent study reported higher incidence of post-infarction cardiac rupture and mortality in mice overexpressing calpastatin. 9 Several reasons, including the different genetic strategy adopted (cardiospecific casp4 deletion, ubiquitous calpastatin deletion or overexpression), the extension of the myocardial infarction, and the duration of the follow-up, could explain these apparently contradictory results. 30 In addition, calpains have been involved in many essential physiological functions, and forced overexpression of calpastatin has been associated with the development of dilated cardiomyopathy, 11 which could interfere with the interpretation of the results obtained in transgenic animals. Furthermore, permanent coronary occlusion models used in these studies does not reflect the situation in patients with acute myocardial infarction receiving urgent reperfusion as recommended in current clinical guidelines. 31 In the present study, the administration of a pharmacological inhibitor either acutely at the onset of reperfusion or chronically starting after 24 h of reperfusion in a model of transient, rather that permanent coronary occlusion, allows differentiating acute effects on infarct size due to reduction of reperfusion injury from a direct modulation of the mechanisms responsible of cardiac remodelling. 32 Pharmacological inhibition of calpains has been so far limited by the low hydrosolubility and membrane permeability of available drugs that difficult reaching effective concentrations in vivo. In this study we used SNJ-1945, a third generation calpain inhibitor, specifically designed to increase its water solubility and bioavailability and less prone to react non-specifically with amino and thiol groups in contrast to other peptidyl inhibitors such leupeptin, calpeptin, and SJA6017. 13, 14 Although it has been suggested that the substrates and actions of calpains and MMP-2 in various cellular pathways overlaps, and it has been demonstrated that some widely used calpain inhibitors also inhibit MMP-2, 24 our results rule-out the possibility that the effects obtained with SNJ-1945 were consequence of an inhibitory action on MMP-2.
In the present study, the attenuation of calpain activation and infarct size measured after 24 h of the administration of a single dose of SNJ- 14 More importantly, our study shows that the oral use of SNJ-1945 starting after coronary occlusion effectively inhibits myocardial calpain activity during prolonged periods of reperfusion. SNJ-1945 was orally administered for 14 days starting 24 h after reperfusion, to minimize any effect on acute reperfusion injury. This oral treatment attenuated LV expansion and dysfunction, and reduced the scar area after 21 days of reperfusion, and attenuated cardiomyocyte hypertrophy, interstitial collagen deposition, and infiltration of inflammatory cells in the non-ischemic area. Importantly, acute treatment with a single intraperitoneal injection of SNJ-1945 had no effect on hypertrophy or collagen infiltration despite reducing infarct size and inflammatory response. When considered together with previous studies, our results suggest that the mechanisms that result in increased calpain activity and the consequences of this activation are different at the onset of reperfusion and during the subsequent remodelling process. At the onset of reperfusion, intracellular Ca 2þ overload and pH i normalization induce the activation of calpains which contributes through the proteolysis of a wide variety of proteins to the necrotic cell death that characterize the acute reperfusion injury. 4 The present study shows that, later during reperfusion, calpain activation is associated to an increased expression of calpain-1 and calpain-2 in the non-ischemic myocardium, in agreement with previous results in models with permanent coronary occlusion. 7, 33 Although the mechanism underlying calpain overexpression and activation during the delayed phase of reperfusion remains to be established, it has been described that conditional overexpression of calpain-1 in cardiomyocytes with physiological intracellular Ca 2þ levels results in increased global calpain activity, inflammatory response, and heart failure. 11 Several mechanisms have been proposed by which calpains may contribute to cardiac remodelling. Calpains can activate the calcineurin/ NFAT pathway by proteolysis of the calcineurin autoinhibitory domain, 34 or by cleavage of its inhibitor cain/cabin1, 35 and thus promote hypertrophy. 36 Besides the activation of transcription factors, calpains have been also implicated in the degradation of N-cadherin, which may induce ventricular remodelling by disassembling cell-cell adhesion at intercalated discs. 8 Finally, different groups suggest that calpains activate caspase-3 during post-infarct remodelling, and therefore, calpain inhibition prevents a progressive loss of cardiomyocytes by apoptosis during the remodelling process. 6, 37 However, this mechanism is unlikely, as a recent study using transgenic mice with cardiospecific deletion of the executioner caspases 3 and 7 demonstrates that apoptosis does not contribute to cardiomyocyte death during postinfarction remodelling. 22 Different studies on remodelling using transgenic mice with cardiomyocyte specific deletion of the calpain small subunit, Capn4, suggest that calpains cleave the inhibitor IOEBa leading to the activation of the NF-OEB pathway. 6, 36 It has been postulated that cardiomyocyte restricted activation of the NF-OEB pathway is sufficient to induce the expression of proinflammatory cytokines that promote infiltration of inflammatory cells, hypertrophy, and fibrosis by activating autocrine and paracrine signalings. 36, 38, 39 In line with these studies, our results demonstrate that delayed inhibition of calpains reduces NF-OEB translocation to the nucleus, attenuates the expression of proinflammatory cytokines and the activation of the TGF-b1/Smad, the canonical pathway involved in tissue fibrosis. Although the results from studies using cardiospecific transgenic models strongly support that calpain activation of NF-OEB in cardiomyocytes trigger the remodelling process, our results in cultured fibroblasts shows that other cardiac cell types may be also targets of calpains. All together, these results suggest that the attenuation of post-infarction remodelling observed with the delayed and chronic administration of SNJ-1945 may be explained at least in part by inhibition of NF-OEB signalling.
In conclusion, our study shows that sustained pharmacological inhibition of calpains is a promising therapeutic strategy against adverse post-infarction ventricular remodelling and maybe accomplished by oral treatment started one day after reperfusion.
Implications
The fact that calpain inhibition was effective when started 24 h after reperfusion is not only mechanistically important, by ruling the contribution of the well-known effect of calpain inhibition on reperfusion injury, but has important translational value. It is well known that even when reperfusion is performed early after symptoms onset, myocardial salvage A B Figure 7 Chronic administration of SNJ-1945 prevents IOEB degradation and reduces NFOEB activation. Representative western-blot and quantification of (A) cytosolic IOEB protein relative to GAPDH and (B) NF-kB p65 protein in the cytosolic and nuclear fractions and expressed relative to histone H3. Results are mean ± S.E.M. *P < 0.05 vs. shamoperated group and $ P < 0.05 vs. control group, n = 5-6 per group). and functional recovery is highly variable in patients with STEMI, and many patients presenting with severe LV dysfunction may have substantially better LV ejection fraction 24 h later. It is thus very important to be able to start anti-remodelling treatments only in patients in whom persistent LV dysfunction and progressive adverse remodelling are expected. Delayed administration of treatments is commonly used in clinical trials on therapies aimed at prevent adverse remodelling in patient with STEMI (BAMI, NCT01569178; CAREMI, NCT02439398). On the other hand, oral administration markedly increases patients compliance and reduces costs, increasing the potential clinical usefulness of calpain inhibition to prevent adverse postinfarction remodelling.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
